Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07811908) titled 'Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Novartis Pharmaceuticals
Condition:
Uncomplicated Plasmodium Falciparum Malaria
Intervention:
Drug: KAE609
Drug: SoC (Coartem)
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: February 12, 2026
Target Sample Size: 120
Countries of Recruitmen...